Search the Newsreel

Definium Therapeutics Stock (DFTX) Opinions on Wells Fargo Coverage

Wells Fargo has initiated coverage on Definium Therapeutics (DFTX) with an overweight rating and a $68 price target, sparking optimism among investors. Despite significant insider selling over the past six months, institutional investors have substantially increased their holdings. Analysts have a median price target …

Wall Street Analysts See a 34.86% Upside in Definium Therapeutics, Inc. (DFTX): Can the Stock Really Move This High?

Definium Therapeutics, Inc. (DFTX) closed at $44.49, and Wall Street analysts project a 34.9% upside with a mean price target of $60. While price targets alone can be misleading, the strong agreement among analysts and a positive trend in earnings estimate revisions suggest potential …

Press Release: Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Definium Therapeutics announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026. The company will also host a conference call and webcast on the same day to discuss the results and provide a business update.

Definium Therapeutics Will Webcast Its Second-Quarter Update Aug. 6

Definium Therapeutics (DFTX) Redefines Depression & Anxiety Treatment

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for "Meridian Small Cap Growth Fund". A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fueled by easing geopolitical tensions, falling …

DFTX Initiates Coverage On Wells Fargo -- Rating Set to Overweig

Wells Fargo has initiated coverage on Definium Therapeutics (DFTX) with an Overweight rating and a price target of $68.00, suggesting significant upside potential from its current trading price. Despite this positive analyst outlook and late-stage pipeline, Definium Therapeutics has a low GF Score™ of …

Wells Fargo Initiates Definium Therapeutics at Overweight

Wells Fargo has initiated coverage of Definium Therapeutics with an "Overweight" rating. Definium Therapeutics (DFTX) is a biotechnology company focused on developing treatments for psychiatric and neurological disorders, with a lead candidate (DT1201 ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD) …

Definium Therapeutics Price Target Raised to $73.00/Share From $48.00 by Piper Sandler

Piper Sandler has increased its price target for Definium Therapeutics to $73.00 per share, up from the previous target of $48.00. This significant adjustment indicates a strong positive outlook from the analytical firm regarding Definium Therapeutics' future valuation.

Piper Sandler raises Definium stock price target on DT120 outlook

Piper Sandler has increased its price target for Definium Therapeutics (NASDAQ:DFTX) shares from $48 to $73, maintaining an Overweight rating due to positive expectations for its DT120 treatment in generalized anxiety and major depressive disorders. This adjustment follows promising Phase III results and a …

Did New Real‑World GAD Data Just Reframe Definium Therapeutics' (DFTX) Late‑Stage Pipeline Potential?

A recent study on Generalized Anxiety Disorder (GAD) revealed significant treatment gaps and unmet needs, which could strengthen the investment narrative for Definium Therapeutics (DFTX). While the study doesn't change immediate clinical catalysts for their DT120 program, it underscores the need for better therapies, …

Definium Therapeutics (DFTX) Highlights GAD Care Gaps, Is The Stock Already Overvalued?

Definium Therapeutics (DFTX) stock has gained significant attention after publishing an analysis on generalized anxiety disorder (GAD) treatment gaps, including frequent treatment switching and early discontinuation. The company's stock has seen substantial returns, with a 30-day gain of 84.15% and a year-to-date return of …

How New GAD Treatment Gap Data At Definium Therapeutics (DFTX) Has Changed Its Investment Story

New data from a large U.S. healthcare claims study indicates significant unmet needs in Generalized Anxiety Disorder (GAD) treatment due to high discontinuation rates, rapid switching, and prolonged pharmacotherapy gaps. This information strengthens Definium Therapeutics' investment narrative by highlighting the critical need for better …

Can Definium Therapeutics (DFTX) Still Be A Bargain Or Fully Priced?

Definium Therapeutics Inc. (DFTX) Fundamental & Financial Data

This article provides fundamental and financial data for Definium Therapeutics Inc. (DFTX), including its current stock price, market capitalization, P/E ratio, and recent news. It also highlights analyst opinions, with one suggesting a potential 32.42% surge for the stock.

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics announced the issuance of inducement grants to two new non-executive employees. These grants consist of options to purchase an aggregate of 30,330 common shares, with an exercise price equal to the closing price on July 20, 2026. The options will vest over …

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

Definium Therapeutics has launched "Wired for Worry," an educational initiative for healthcare providers focusing on Generalized Anxiety Disorder (GAD). This program aims to deepen understanding of GAD's symptoms, lifelong impact, and neurobiology, as well as the importance of early identification through tools like the …

Definium Therapeutics Inc. (DFTX) News, Articles, Events & Latest Updates

This page provides a collection of recent news, articles, and updates concerning Definium Therapeutics Inc. (DFTX), a late-stage clinical biopharmaceutical company. Key topics include analyst price targets, a new healthcare claims study on Generalized Anxiety Disorder, positive clinical trial updates for depression treatment, and …

Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?

Definium Therapeutics (DFTX) Sees Significant Gains

Definium Therapeutics (DFTX) Lands Phase 3 Win And Raises $700 Million For DT120

Definium sets webcast on Phase 3 depression study results for June 22

Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent?

Earnings call transcript: Definium’s Q1 2026 EPS miss overshadows strategic advances

Definium Therapeutics Q1 Earnings Call Highlights

DFTX: Definium Therapeutics, Inc. - Full Company Report

Can Definium Therapeutics (DFTX) Turn GAD Prevalence And DT120 Breakthrough Status Into Durable Advantage?

Definium Therapeutics Q4 Earnings Call Highlights

A Look At Definium Therapeutics (DFTX) Valuation After Recent Double Digit Share Price Returns

What date does Definium Therapeutics, Inc.'s (DFTX) report Earnings - Earnings Calendar & Announcement